Cargando…

SAT-582 Autoimmune Hepatitis Presenting with Graves Disease

Graves disease, the most common cause of hyperthyroidism in the world has an incidence peak between 30 and 50 years of age. It is more frequent in women that in men with a ratio of 5:1. The typical presentation is thyrotoxicosis, goiter and opthalmopathy. The most specific laboratory finding is the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Coy, Andres, Sanchez, Pedro, Rojas, William, Hernandez, Diana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Endocrine Society 2019
Materias:	Thyroid
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6551903/ http://dx.doi.org/10.1210/js.2019-SAT-582

Ejemplares similares

SAT-588 Unique Presentation of Postpartum Thyroiditis with Features of Graves' Disease
por: Havranova, Jana, et al.
Publicado: (2019)

SAT-580 Tocilizumab Improvement in a Patient with Corticosteroid Resistant Thyroid Orbitopathy: Report of a Case
por: Coy, Andres, et al.
Publicado: (2019)

SAT-476 Alemtuzumab Induced Graves Disease
por: Caputi, Rafael C, et al.
Publicado: (2020)

SAT489 Grave’s Disease Secondary To Alemtuzumabuse
por: Gong, Michael Shifeng, et al.
Publicado: (2023)

SUN-502 Graves’Disease and Autoimmune Hepatitis: Management Challenges
por: Soares, Maria Marta Sarquis, et al.
Publicado: (2020)

SAT-603 Graves' Disease and an Anterior Mediastinal Mass
por: Robbins, D'lorah, et al.
Publicado: (2019)

SAT-592 Amiodarone-Induced Cure Of Graves' Disease
por: Sharma, Eliza, et al.
Publicado: (2019)

SAT-605 Immune Thrombocytopenic Purpura in Graves' disease
por: Sajja, Puspalatha, et al.
Publicado: (2019)

SAT-429 Systemic Safety Analysis of Mycophenolate in Graves’ Orbitopathy
por: Lee, Alan C H, et al.
Publicado: (2020)

SAT-428 Sex-Specific Risk Gene of Graves’ Disease
por: Zhao, Shuangxia, et al.
Publicado: (2020)

SAT462 TSI Versus TRAb In The Diagnosis Of Grave’s Disease
por: Ibrahim, Katherine, et al.
Publicado: (2023)

SUN-508 Dissociation of Clinical Course of Coexisting Autoimmune Hepatitis and Graves Disease
por: Patel, Aesha, et al.
Publicado: (2020)

SAT490 Graves’ Disease In Remission Aggravated By Himalayan Salt Consumption
por: Shakir, Mohamed K M, et al.
Publicado: (2023)

SAT-557 Functional Thyrotropin Receptor Antibodies Confirm a Novel Graves' Disease Animal Model
por: Diana, Tanja, et al.
Publicado: (2019)

SAT-581 Graves' Disease and Hashimoto's Thyroiditis: Two Ends of a Spectrum
por: Morselli, Lisa, et al.
Publicado: (2019)

SAT-463 Thyrotoxicosis from Nivolumab in a Patient with Preexisting Graves’ Disease
por: Polavarapu, Preethi, et al.
Publicado: (2020)

SAT-413 Does Dipeptidyl Peptidase-4 Inhibitor Exacerbate Graves’ Disease?
por: Sekizaki, Tomonori, et al.
Publicado: (2020)

SAT-415 Clinical Performance of Thyroid-Stimulating Immunoglobulin for Graves′ Disease Diagnosis
por: Marui, Suemi, et al.
Publicado: (2020)

SAT-497 Conversion of Hashimoto’s Thyroiditis to Grave’s Disease: A Case Report
por: Wahedi, Tayba S, et al.
Publicado: (2020)

SUN-567 Moyamoya and Autoimmune Graves' Disease
por: Elagi, Daniyah, et al.
Publicado: (2019)

SAT-604 Immunoglobulin G4-related Disease In A Patient With Graves' Disease
por: Ozgen Saydam, Basak, et al.
Publicado: (2019)

SAT474 A Case Report Of Moyamoya Disease Associated With Uncontrolled Graves' Disease
por: Tan, Zi, et al.
Publicado: (2023)

SAT-554 Teprotumumab in Graves' Orbitopathy: Extended Outcome Analyses
por: Kahaly, George, et al.
Publicado: (2019)

SAT-459 A Grave Complication: Pulmonary Arterial Hypertension
por: Butt, Wajeeha Saeed, et al.
Publicado: (2020)

SAT-498 Graves’-Associated Takotsubo Cardiomyopathy: An Uncommon Condition
por: Mortensen, Michael, et al.
Publicado: (2020)

SAT-423 Anti-thyroid Drug Response in Graves’ Disease: Predictors of Biochemically Persistent Disease
por: El Kawkgi, Omar M, et al.
Publicado: (2020)

FRI567 Insulin Autoimmune Syndrome And Grave’s Disease
por: Skariah, Annie M, et al.
Publicado: (2023)

SAT488 Wolff-Chaikoff’s Revenge: There-and-Back Again Graves Thyrotoxicosis
por: Akofu, Anota, et al.
Publicado: (2023)

A Grave Initial Presentation of Graves’ Disease in a Patient With Moyamoya
por: Clutter, Courtney, et al.
Publicado: (2021)

SAT-518 Progression of Graves Disease to Hashimoto’s Thyroiditis Following Alemtuzumab Therapy for Multiple Sclerosis
por: Rapier, Brandon, et al.
Publicado: (2020)

SAT-456 Reduced Cholesterol Absorption and Synthesis Markers in Patients with Hyperthyroidism Due to Graves’ Disease
por: Nagamine, Tomoko, et al.
Publicado: (2020)

SAT495 Persistent Euthyroid State in a Patient with Biochemical and Imaging Evidence of Graves' Disease
por: Antony, Mc Anto, et al.
Publicado: (2023)

SAT553 A Case of Metastatic Functional Papillary Thyroid Cancer in the Setting of Graves’ Disease
por: Manuel, Nicholas, et al.
Publicado: (2023)

SAT461 Hearing-related Issues Associated With Graves’ Disease, Thyroid Eye Disease And Treatment With Teprotumumab
por: Smith, Terry J, et al.
Publicado: (2023)

SUN-582 Peripartum Central Hypothyroidism: A Case to Consider
por: Caputi, Rafael, et al.
Publicado: (2019)

Presentation and Outcome of Severe Graves’ Disease
por: Babu, Priya Mohan, et al.
Publicado: (2021)

SAT-471 A Rare Case of Pretibial Myxedema Preceding Graves’ Hyperthyroidism
por: Bao, Ginny W, et al.
Publicado: (2020)

A Case of Rare Autoimmune Pancytopenia Due to Graves’ Disease
por: Wang, Ally Wen, et al.
Publicado: (2021)

SAT-625 Dose-Dependent, Methimazole-Induced Agranulocytosis in a Pregnant Hispanic Woman with Grave's Disease
por: Bello, Fatimah, et al.
Publicado: (2019)

SAT-412 Genetic Susceptibility to Graves’ Disease Conferred by HLA-DQβ1 Position 57
por: Badenhoop, Klaus, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ncldsvtt4m50av10a6t4ithvtu